What can the investigation of phosphoinositide signaling system In platelets of schizophrenic patients tell us?

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 61, Issue 1, 1999, Pages 1-5

  Strunecka A ^a   Ripov D ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCIUM ION; INOSITOL PHOSPHATE; PHOSPHATIDYLINOSITIDE;

CALCIUM HOMEOSTASIS; HUMAN; HUMAN CELL; LABORATORY TEST; PATHOGENESIS; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOCYTE;

EID: 0345425031     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1999.0063     Document Type: Article

References (47)

1. Feighner J. P., Robins E., Guze S. B., Woodruff R. A., Winokur G., Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 26:1972;57-63.
2. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. 1994;American Psychiatric Association, Washington.
3. Carpenter W. T., Buchanan R. W. Schizophrenia. N Engl J Med. 330:1994;681-690.
4. Wirz-Justice A. Platelet research in psychiatry. Experientia. 44:1988;145-152.
5. Barradas M. A., Mikhailidis D. P. The use of platelets as models for neurons: possible applications to the investigation of eating disorders. Biomed Pharmacother. 47:1993;11-18.
6. Kafka M. S., Van Kammen D. P., Bunney W. E. Reduced cyclic AMP production in the blood platelets from schizophrenic patients. Am J Psychiatry. 136:1979;685-694.
7. Garver D. M., Johnson C., Kanter D. R. Schizophrenia and reduced cyclic AMP production: Evidence for the role of receptor-linked events. Life Sci. 31:1982;1987-1992.
8. Losonczy M. . F., Davidson M., Davis K. L. The dopamine hypothesis of schizophrenia. Meltzer H. Y. Psychopharmacology: The Third Generation of Progress. 1987;715-725 Raven Press, New York.
9. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
10. Davis K. L., Kahn R. S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 148:1991;1474-1486.
11. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
12. Rotrosen, J. Wolkin, A. Phospholipid and prostaglandin hypotheses of schizophrenia, Meltzler, H. Y. Psychopharmacology: The Third Generation of Progress, Raven Press, New York, 1987, 759, 764.
13. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson disease. Trends Neurosci. 13:1990;272-276.
14. Mass J. W., Contreras S. A., Miller A. L. Studies of catecholamine metabolism in schizophrenia psychosis. I Neuropsychopharmacology. 8:1993;97-109.
15. 2activity in shizophrenia. A replication study. Biol Psychiatry. 28:1990;495-501.
16. 2in the pathogenesis of schizophrenia. Č S Psychiatry. 91:1995;259-264.
17. Berridge M. J., Irvine R. F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 312:1984;315-321.
18. Rana R. S., Hokin L. E. Role of phosphoinositides in transmembrane signaling. Physiol Rev. 70:1990;115-164.
19. Berridge M. J. Inositol trisphosphate and calcium signalling. Nature. 361:1993;315-325.
20. Nishizuka Y. Perspectives on the role of protein kinase C in stimulus-response coupling. JNCI. 76:1986;363-370.
21. Berridge M. J. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem. 56:1987;159-193.
22. Hokin L. E., Hokin M. R. Acetylcholine and the exchange of inositol and phosphate in brain phosphoinositide. J Biol Chem. 233:1958;818-821.
23. 32P into phosphatides in slices from the guinea pig brain. J Neurochem. 17:1970;357-364.
24. Abdel-Latif A. A., Zau S. J., Smith J. P. Effect of neurotransmitters on phospholipid metabolism in rat cerebral-cortex slices-cellular and subcellular distribution. J Neurochem. 22:1974;383-393.
25. Friedel R. O., Berry D. E., Schanberg S. M. Effects of dopamine and norepinephrine on phospholipid metabolism of rat brain in vivo: regional differences. J Neurochem. 22:1974;873-875.
26. 2dopamine receptors in dissociated bovine anterior pituitary cells. Neurosci Lett. 60:1985;267-272.
27. Berridge M. J., Downess C. P., Hanley M. R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J. 206:1982;587-595.
28. Kaiya H., Nishida A., Imai A., Nakashima S., Nozawa Y. Accumulation of diacylglycerol in platelet phosphoinositide turnover in schizophrenia: A biological marker of good prognosis? Biol Psychiatry. 26:1989;669-676.
29. Siess W. Multiple signal-transduction pathways synergize in platelet activation. News Phys Sci. 6:1991;51-56.
30. Essali M. A., Das I., de Belleroche J., Hirsch S. R. The platelet polyphosphoinositide system in schizophrenia: The effects of neuroleptic treatment. Biol Psychiatry. 28:1990;475-487.
31. Yao J. K., Yasaei P., van Kammen D. P. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 46:1992;39-46.
32. Řípová D., Strunecká A., Farská I., Němcová V. Calcium induced alterations in phospholipids in platelets of schizophrenic patients. Physiol Res. 46:1997;59-68.
33. Cocroft S., Thomas G. M. H. Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J. 288:1992;1-14.
34. Sherman W. R., Gish B. G., Honchar M. P., Munsell L. Y. Effects of lithium on phosphoinositide metabolism in vivo. Federation Proc. 45:1986;2639-2646.
35. Ackermann K. E., Gish B. G., Honchar M. P., Sherman W. R. Evidence that inositol 1-phosphate in brain of lithium-treated rats results mainly from phosphatidylinositol metabolism. Biochem J. 242:1987;517-524.
36. Demisch L., Heinz K., Gerbaldo H., Kirsten R. Increased concentration of phosphatidylinositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Prostaglandins Leukot Essent Fatty Acids. 46:1992;47-52.
37. Strunecká A., El-Desouki N. I., Palecček J., KmoníčkovØ E., Krpejšov L., Potter B. V. The effect of inositol 1,4,5-trisphosphate and inositol 1,4,5-trisphosphorothioate on calcium release in the human red blood cell. Receptor. 1:1991;141-154.
38. Bashford C. L., Alder G. M., Menestrina G., Micklem K. J., Murphy J. J., Pasternak C. A. Membrane damage by hemolytic viruses, toxins, complement, and other cytotoxic agents. J Biol Chem. 261:1986;9300-9308.
39. Wyatt R. J. Neurodevelopmental abnormalities and schizophrenia. Arch Gen Psychiatry. 53:1996;11-14.
40. Kaufmann, C. A. Ziegler, R. J. The viral hypothesis of schizophrenia, Sen, A. K.Lee, T. Receptor and ligands in psychiatry, Cambridge University Press, Cambridge, 1988, 187, 208.
41. Waltrip R. W. II, Carrigan D. R., Carpenter W. T. Jr. Immunopathology and viral reactivation: a general theory of schizophrenia. J Nerv Ment Dis. 178:1990;729-738.
42. 2- and phospholipase C metabolites. Life Sci. 49:1991;247-259.
43. Kafka M. S., van Kammen D. P. Alpha-Adrenergic receptor function in schizophrenia. Arch Gen Psychiatry. 40:1983;264-270.
44. Horrobin D. F. Dopamine supersensitivity, endorphin excess, and prostaglandin E1 deficiency: three aspects of the same schizophrenic elephant. Schizophr Bull. 4:1978;487-488.
45. Kaiya H. Second messenger imbalance hypothesis of schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 46:1992;33-38.
46. 2by diacylglycerol. Biochem J. 248:1987;779-783.
47. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W. H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 291:1993;677-680.